Opinion

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson/mayoclinic.org

Nov 1, 2024, 12:08

Thor Halfdanarson: The risk of recurrence following resection of pNETs

Thor Halfdanarson, Vice President at the North American Neuroendocrine Tumor Society, shared on X:

“This is going to be a favorite paper in the clinic when counseling patients on risk of recurrence following resection of pNETs. Node negativity and absence of lymphovascular invasion predict a very favorable outcome and low recurrence risk.”

Thor Halfdanarson

Incidence and Prognostic Implications of Lymphovascular Invasion in Node-Negative Pancreatic Neuroendocrine Tumors: Results From the US Neuroendocrine Study Group

Authors: Kota Sahara, Diamantis I. Tsilimigras, Yuki Homma, Jun Kawashima, Shishir K. Maithel, Flavio Rocha, Sharon Weber, Ryan Fields, Kamran Idrees, George A. Poultsides, Cliff Cho, Itaru Endo, Timothy M. Pawlik

Thor Halfdanarson

More posts featuring Thor Halfdanarson.

cancer Cliff Cho Diamantis I. Tsilimigras Flavio Rocha George A. Poultsides Itaru Endo Jun Kawashima Kamran Idrees Kota Sahara OncoDaily oncoology Ryan Fields Sharon Weber Shishir K. Maithel Thor Halfdanarson Timothy M. Pawlik Yuki Homma

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...